GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synageva BioPharma Corp (FRA:TMS1) » Definitions » Cyclically Adjusted FCF per Share

Synageva BioPharma (FRA:TMS1) Cyclically Adjusted FCF per Share : €0.00 (As of Mar. 2015)


View and export this data going back to . Start your Free Trial

What is Synageva BioPharma Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Synageva BioPharma's adjusted free cash flow per share for the three months ended in Mar. 2015 was €-1.246. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Mar. 2015.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-09), Synageva BioPharma's current stock price is €211.31. Synageva BioPharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2015 was €0.00. Synageva BioPharma's Cyclically Adjusted Price-to-FCF of today is .


Synageva BioPharma Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Synageva BioPharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synageva BioPharma Cyclically Adjusted FCF per Share Chart

Synageva BioPharma Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synageva BioPharma Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Synageva BioPharma's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Synageva BioPharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synageva BioPharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synageva BioPharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Synageva BioPharma's Cyclically Adjusted Price-to-FCF falls into.



Synageva BioPharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Synageva BioPharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2015 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2015 (Change)*Current CPI (Mar. 2015)
=-1.246/99.6211*99.6211
=-1.246

Current CPI (Mar. 2015) = 99.6211.

Synageva BioPharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200506 -0.942 82.062 -1.144
200509 -0.521 83.876 -0.619
200512 -0.770 83.032 -0.924
200603 0.844 84.298 0.997
200606 0.005 85.606 0.006
200609 0.489 85.606 0.569
200612 0.702 85.142 0.821
200703 1.015 86.640 1.167
200706 0.700 87.906 0.793
200709 0.708 87.964 0.802
200712 1.004 88.616 1.129
200803 1.357 90.090 1.501
200806 0.434 92.320 0.468
200809 0.361 92.307 0.390
200812 0.280 88.697 0.314
200903 0.244 89.744 0.271
200906 0.147 91.003 0.161
200909 0.232 91.120 0.254
200912 1.972 91.111 2.156
201003 -0.130 91.821 -0.141
201006 -0.141 91.962 -0.153
201009 -0.469 92.162 -0.507
201012 -1.157 92.474 -1.246
201103 -54.193 94.283 -57.261
201106 -47.351 95.235 -49.532
201109 -29.122 95.727 -30.307
201112 -0.328 95.213 -0.343
201203 -0.226 96.783 -0.233
201206 -0.009 96.819 -0.009
201209 -0.445 97.633 -0.454
201212 -0.456 96.871 -0.469
201303 -0.563 98.209 -0.571
201306 -0.598 98.518 -0.605
201309 -0.539 98.790 -0.544
201312 -0.681 98.326 -0.690
201403 -0.860 99.695 -0.859
201406 -0.917 100.560 -0.908
201409 -1.059 100.428 -1.050
201412 -1.051 99.070 -1.057
201503 -1.246 99.621 -1.246

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Synageva BioPharma  (FRA:TMS1) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Synageva BioPharma Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Synageva BioPharma's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Synageva BioPharma (FRA:TMS1) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Synageva BioPharma Corp is incorporated in Delaware in 1993. On November 2, 2011, Trimeris, Inc., a Delaware corporation closed a merger transaction, Reverse Merger with Synageva BioPharma Corp., Pursuant to the Merger Agreement, Private Synageva became a wholly owned subsidiary of Trimeris. As a Reverse Merger, Trimeris changed its name to Synageva BioPharma Corp. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The Company has several proteins therapeutic in its pipeline, including enzyme replacement therapies for lysosomal storage diseases (LSDs) and protein therapeutic programs for other rare diseases that are at the stage of preclinical development. Its program, sebelipase alfa is a recombinant human lysosomal acid lipase deficiency (LAL Deficiency), currently evaluating in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. LAL Deficiency is rare autosomal recessive LSD characterized by decreased LAL enzyme activity leading to intracellular accumulation of lipids. This disease leads to medical complications with significant morbidity and early mortality. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants. The Company has not yet received approval to market this product and is not currently commercializing any other products. Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing Phase 3 Trial of Sebelipase Alfa in Children and Adults with LAL Deficiency. It is also pursuing a development strategy for sebelipase alfa to assess safety and tolerability in a broad population of patients, including infants, children, and adults, and to demonstrate efficacy, safety and tolerability of sebelipase alfa in the treatment of LAL Deficiency. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.

Synageva BioPharma (FRA:TMS1) Headlines

No Headlines